Clinical Report: Severe Hypertriglyceridemia Linked to Asparaginase in Children
Overview
This study examines the incidence and management of severe asparaginase-induced hypertriglyceridemia (AIHTG) in pediatric patients with acute lymphoblastic leukemia (ALL). Among 598 patients treated, 12 experienced severe AIHTG, primarily asymptomatic.
Background
Asparaginase is a critical component of ALL treatment, but it is associated with various metabolic adverse effects, including hypertriglyceridemia. This study provides insights into the clinical characteristics and outcomes of severe AIHTG in a single-center cohort.
Data Highlights
Parameter
Value
Incidence of severe AIHTG
2%
Median age of patients
9.5 years
Median peak triglyceride concentration
2,645 mg/dL
Asymptomatic cases
83%
Management interventions
IV fluids, omega-3 fatty acids, fibrates, insulin infusion
Key Findings
12 out of 598 pediatric ALL patients developed severe AIHTG (2% incidence).
83% of cases were asymptomatic, identified through routine lab tests.
Median peak triglyceride levels reached 2,645 mg/dL.
Management included intravenous fluids, omega-3 fatty acids, fibrates, and insulin infusion.
Plasmapheresis was performed in three patients with triglyceride levels exceeding 6,000 mg/dL.
Asparaginase was resumed in eight patients after ensuring triglyceride levels were below 1,000 mg/dL.
Clinical Implications
Timely detection of AIHTG is crucial, as most cases are asymptomatic and can lead to significant complications if not managed properly.
Conclusion
Severe AIHTG is a significant concern in pediatric ALL treatment, often asymptomatic but requiring intervention.
